Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16775228.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Spinal muscular atrophy (SMA) is a recessively inherited motor neuron disease caused by deficient survival motor neuron (SMN) protein. Valproate increases SMN protein in vitro by increasing transcription of SMN2 genes. The authors treated seven adult patients with SMA type III/IV with valproate for a mean duration of 8 months. The treated patients with SMA had increased quantitative muscle strength and subjective function. Further trials of valproate treatment for SMA type III/IV are warranted.
Medical subject headings
- Motor Neurons
- Muscular Atrophy, Spinal
- Valproic Acid